Condition evidence map
Obesity
Research evidence map for obesity: the SCALE, STEP, SURMOUNT and Phase 2 retatrutide weight-management programmes, dose-response and discontinuation data, and UK MHRA/NICE positioning.
Research context
Obesity (BMI ≥30, or ≥27.5 in South Asian populations) affects roughly 28% of adults in England, with a further ~38% overweight; the NHS estimated the direct cost of overweight and obesity at £6.1 billion a year in 2023. Historically resistant to durable pharmacotherapy, obesity has been transformed by the incretin class across four programmes: SCALE (liraglutide 3.0 mg, 2015; ~8.0% vs 2.6% placebo at 56 weeks), STEP (semaglutide 2.4 mg, 2021–22; STEP-1 ~14.9% at 68 weeks), SURMOUNT (tirzepatide, 2022–23; SURMOUNT-1 ~15.0/19.5/20.9% at the 5/10/15 mg doses over 72 weeks), and the Phase 2 retatrutide trial (2023; ~24.2% at 12 mg over 48 weeks — the largest mean reduction reported at publication, with no apparent plateau). STEP-4 and SURMOUNT-4 characterise weight regain after discontinuation; SELECT extended the evidence to cardiovascular outcomes.
Why this matters metabolically
GLP-1 receptors are broadly expressed — hypothalamus, brainstem, vagal afferents, gastric smooth muscle, pancreatic islets — so agonism reduces energy intake through central appetite/satiety signalling and slowed gastric emptying, cutting ad libitum intake by roughly 500–800 kcal/day at therapeutic doses. Adding GIP agonism (tirzepatide) contributes adipose-tissue effects (lipolysis, adiponectin, macrophage polarisation), and adding glucagon agonism (retatrutide) raises resting energy expenditure via hepatic fatty-acid oxidation — a plausible third additive axis. This multi-node pharmacology distinguishes the class from earlier single-pathway weight-loss agents (sibutramine, rimonabant).
FAQs
- What is the maximum mean weight reduction documented in a phase 3 obesity trial?
- As of 2025, tirzepatide 15 mg produced the largest mean weight reduction in a completed phase 3 RCT: approximately 22.5% at 72 weeks in SURMOUNT-1. Among GLP-1 monoagonists, semaglutide 2.4 mg achieved approximately 14.9% in STEP-1. The Phase 2 retatrutide trial reported approximately 24.2% at 48 weeks, but this was an early-phase trial with a smaller sample and shorter duration.
- How does the STEP programme differ from SURMOUNT?
- STEP (STEP-1 through STEP-8) evaluated semaglutide 2.4 mg weekly across diverse populations — without T2D (STEP-1), with T2D (STEP-2), maintenance (STEP-3/4), adolescents, and with cardiovascular disease (SELECT). SURMOUNT-1 to -4 evaluated tirzepatide 5/10/15 mg in adults without T2D, with T2D (SURMOUNT-2), with a dietary lead-in (SURMOUNT-3), and for weight maintenance (SURMOUNT-4).
- What were the SCALE trials and what did they show?
- SCALE was a programme of phase 3 trials for liraglutide 3.0 mg (Saxenda) in obesity. SCALE Obesity and Prediabetes showed a mean weight reduction of approximately 8.0% at 56 weeks versus 2.6% with placebo — substantially lower than the later STEP and SURMOUNT results, reflecting daily dosing, lower receptor binding affinity and the absence of GIP co-agonism.
- What does the retatrutide Phase 2 data suggest about weight-reduction trajectories?
- The Phase 2 retatrutide trial (NEJM 2023) reported approximately 24.2% mean weight reduction at 12 mg weekly over 48 weeks, with the weight-loss curve not yet plateauing — suggesting continued divergence with longer treatment and driving interest in whether triple-receptor agonism (GLP-1/GIP/glucagon) yields a different weight set-point than dual agonism. Phase 3 (TRIUMPH) is the confirmatory test.
- How much weight regain occurs after stopping semaglutide?
- STEP-4 randomised participants who had lost weight on semaglutide 2.4 mg to continue or switch to placebo. Those switched to placebo regained approximately two-thirds of their lost weight over the subsequent 48-week withdrawal period, with cardiometabolic improvements largely reversing — underpinning the framing of obesity as a chronic condition requiring long-term management rather than a short course.
- Trial-cohort mean weight reductions do not predict any individual's response.
- Weight-reduction magnitude does not by itself establish cardiovascular, hepatic or long-term outcome benefit.
- Predominantly female, White trial populations may not generalise uniformly across UK ethnicities.
- Absence of beyond-5-year safety and weight-maintenance data is an open limitation for the whole class.
Related mechanisms
Related peptide profiles
Related trials
Related safety signals
Related conditions
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022.
- Peer-reviewed publicationWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
- Peer-reviewed publicationLincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023.
- Peer-reviewed publicationJastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med 2023.
- Peer-reviewed publicationPi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). N Engl J Med 2015.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)NICE — National Institute for Health and Care Excellence
NICE guidance on treatment pathways for metabolic conditions
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of condition profiles on this site